Ballantyne's Syndrome (Mirror Syndrome)
Ballantyne's syndrome, also known as mirror syndrome or triple-edema syndrome, is an uncommon maternal complication in which the mother develops edema that "mirrors" the edema of her hydropic fetus, characterized by the triad of fetal hydrops, maternal edema, and placentomegaly. 1
Clinical Presentation
The syndrome presents with a characteristic pattern of maternal findings that develop in association with fetal hydrops:
Maternal Features
- Edema occurs in approximately 80-100% of cases, representing the hallmark feature 2
- Hypertension develops in 57-78% of patients 2
- Proteinuria is present in 20-56% of cases 1, 2
- Additional manifestations include headache, visual disturbances, oliguria, elevated uric acid, abnormal liver function tests, elevated creatinine, thrombocytopenia, anemia, and hemodilution 1
Fetal and Placental Components
Pathophysiology
Mirror syndrome may represent a form of preeclampsia, with similar underlying mechanisms 1. The same imbalance of angiogenic and anti-angiogenic factors described in severe preeclampsia has been observed in mirror syndrome cases 1. Specifically, elevated maternal plasma concentrations of soluble VEGF receptor-1 (sVEGFR-1), an anti-angiogenic factor, have been documented in mirror syndrome patients, with all affected patients showing sVEGFR-1 levels above the 95th percentile for gestational age 5.
Associated Conditions
Mirror syndrome can develop in association with any cause of fetal hydrops, including:
- Rhesus isoimmunization (29% of cases) 2
- Twin-twin transfusion syndrome (18%) 2
- Viral infections (16%) 2
- Fetal malformations, fetal or placental tumors (37.5%) 2
- Fetal arrhythmias, hydrothorax, parvovirus infection, and bladder obstruction 1
- Fetal lung lesions and severe fetal anemia 3
Diagnosis and Recognition
The diagnosis is often missed or delayed because mirror syndrome is frequently misdiagnosed as preeclampsia 6. The condition is likely more prevalent than current data suggests due to underdiagnosis 6. Mean gestational age at diagnosis ranges from 22.5 to 27.8 weeks 2, though it can present at 27.0 ± 3.8 weeks on average 3.
A critical diagnostic pitfall is that mirror syndrome may develop following fetal therapeutic intervention in up to 66.6% of cases, necessitating heightened maternal surveillance after any fetal procedure for hydrops 3.
Maternal Complications and Prognosis
The major maternal morbidity is pulmonary edema, which occurs in 21% of cases 1, 2. The syndrome is associated with substantial maternal morbidity, though maternal symptoms typically resolve 4.8-13.5 days after delivery 2.
Resolution can occur with either treatment of the underlying fetal hydrops or with delivery 1. In cases where successful fetal intervention resolves the hydrops, maternal mirror syndrome symptoms can improve or completely resolve before delivery, with a mean interval from intervention to maternal recovery of 13.1 days (range 4-35 days) 3.
Management Approach
For most cases of nonimmune hydrops fetalis (NIHF), including all cases without a treatable etiology, development of mirror syndrome necessitates delivery 1. This represents a firm recommendation from the Society for Maternal-Fetal Medicine 1.
Treatment Strategy Based on Etiology
When mirror syndrome is associated with treatable causes of fetal hydrops (such as fetal arrhythmia, hydrothorax, parvovirus infection, or bladder obstruction), there have been documented cases of resolution of both the hydrops and mirror syndrome following treatment 1. Treatment options may include:
- Intrauterine transfusion for fetal anemia 1
- Antiarrhythmic medications for fetal arrhythmias 1
- Drainage of large pleural effusions 1
- Laser coagulation for twin-twin transfusion syndrome 1
Important Caveats
However, there are no data regarding the likelihood of resolution or long-term benefits of expectant management 1. Given the risks of expectant management of severe preeclampsia, this approach should be taken only with caution, and delivery should not be delayed if the maternal condition deteriorates 1.
Serial evaluation of maternal blood pressure is recommended in all cases of NIHF to monitor for development of mirror syndrome 1.
Fetal Outcomes
The overall rate of intrauterine fetal death is 56%, reflecting the severity of underlying conditions 2. Fetal mortality can be as high as 67.2% 6. Among treated pregnancies, outcomes include approximately 55.5% livebirths, 25.9% neonatal deaths, and 18.5% intrauterine deaths 3.